FDA official logo
GSRS logo
PFDA official logo

PINATUZUMAB VEDOTIN

  • UNII: 6KA1906BLC
  • Preferred Substance Name: PINATUZUMAB VEDOTIN

  • 1313706-14-7
  • ACD22-VCMMAE
  • ACD-22VCMMAE
  • ACD-22-VCMMAE
  • ANTI-CD22-MONOMETHYL AURISTATIN E ANTIBODY-DRUG CONJUGATE
  • DCDT2980S
  • DCDT-2980S
  • FCU2703
  • FCU-2703
  • IMMUNOGLOBULIN G1-KAPPA AURISTATIN E CONJUGATE, ANTI-(HOMO SAPIENS CD22 (SIALIC ACID BINDING IG-LIKE LECTIN 2, SIGLEC2, SIGLEC-2, BLYMPHOCYTE CELL ADHESION MOLECULE, BL-CAM, LEU-14)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E
  • PINATUZUMAB VEDOTIN [INN]
  • PINATUZUMAB VEDOTIN [USAN]
  • PINATUZUMAB VEDOTIN [WHO-DD]
  • RG-7593
  • RO5541072-000
  • RO-5541072000
  • RO-5541072-000

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo